Trial Profile

An Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 03 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Apraglutide (Primary)
Indications Intestinal failure; Short bowel syndrome
Focus Adverse reactions; Registrational
Acronyms STARS extend
Sponsors Ironwood Pharmaceuticals; VectivBio

Most Recent Events

29 Jan 2025 According to an Ironwood Pharmaceuticals media release, company announced that they haveInitiated rolling NDA submission, now to include long-term extension data given continued clinical improvement over time, with submission completion expected in Q3 2025
12 Jan 2024 According to an Ironwood Pharmaceuticals media release, the VectivBio has been acquired and merged into Ironwood Pharmaceuticals.
08 Jan 2024 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com